How Do You Know a Dry Eye Treatment Worked?

By Dr. Chris Wolfe

When I ask large audiences how they know whether a dry eye treatment worked, the best and worst answer I get is, “the patient will tell me.”

It is the best answer because dry eye is a symptom-driven disease. At the end of the day, we do want the patient to feel better. If their eyes are more comfortable, their vision is more stable, and they can get through the day with less irritation, that matters.

But it is also the worst answer because, for many doctors, that is the only answer they have.

And if that is your only method of assessment, dry eye will always feel uncertain.

That uncertainty is what makes many doctors apprehensive about building a dry eye practice. They are not necessarily afraid of making the diagnosis. They are afraid of the follow-up visit. They are afraid of the patient who returns after an expensive treatment, or a prescription with side effects, and says, “It didn’t work.”

If your only framework is the patient’s immediate impression, that moment feels like failure.

But in many cases, it is not treatment failure at all. It is a failure to assess the disease systematically.

Dry eye is not a condition you should evaluate by simply asking, “Did that work?” Dry eye should be evaluated the same way we evaluate any other chronic disease: by comparing baseline symptoms and objective findings to follow-up symptoms and objective findings over an appropriate timeline.

That is the expectation doctors need to have if they want to build confidence in dry eye care and improve the current state of their dry eye practice.

Start with the right expectation

One of the biggest mistakes we make in dry eye is expecting symptom improvement to behave like an acute problem. We want a patient to use a treatment, come back, and say, “Wow, I feel dramatically better.”

Some patients will do that. Many will not.

Dry eye usually gets worse gradually over months, years, and sometimes decades. Because that decline is slow, patients often do not appreciate how much they have worsened. If most patients went from minimal symptoms to moderate or severe symptoms overnight, they would be pounding on your door begging to be seen. But because the decline is gradual, they adapt.

The same thing happens in reverse.

When dry eye improves, that improvement is often slow and incremental. A patient may be better without being fully aware that they are better. They may say they are “about the same” when their signs are improved and their symptom score is better. They may be unsure. They may feel the change is minimal. They may even think nothing has changed at all.

That does not mean the treatment failed. It means the disease is chronic, the improvement is gradual, and your job is to measure that change better than the patient can feel it in real time.

If that sounds strange, think about glaucoma.

If a glaucoma patient comes back after using a medication or having an SLT and says, “My eyes feel exactly the same,” we do not throw our hands in the air and conclude the treatment failed. We look at the intraocular pressure. We assess the objective findings. Then we tell them whether the treatment was successful.

Dry eye deserves the same kind of thinking.

The current state of many dry eye practices

The current state in many practices is that doctors do treat dry eye, but they do not always have a consistent system for deciding why they chose a treatment, when they should reassess it, and how they will know whether it helped.

That is why dry eye can feel unpredictable.

The problem is usually not that the doctor lacks intelligence or compassion. The problem is that “dry eye” gets treated like one bucket diagnosis. A patient has irritation, fluctuation, burning, tearing, or discomfort, and the chart says dry eye. Treatment is selected. Then everyone waits to hear whether the patient liked it.

That is not a system. That is hope.

The better way to think about dry eye is to separate the disease into its dominant mechanism. Broadly speaking, that means asking whether the patient’s problem is primarily:

• evaporative,
• inflammatory, or
• aqueous deficient.

Yes, there is overlap. Yes, mucin matters. Yes, there are zebras. But for the purpose of practical clinical decision-making, most doctors will improve dramatically if they learn to ask one simple question: what is the dominant mechanism here?

Because many “failed” treatments are not true treatment failures. They are diagnostic mismatches.

If the dominant problem is evaporative disease and you chose a treatment better suited for aqueous deficiency, the treatment did not fail. Your assessment did.

If the dominant problem is inflammatory and you selected a therapy aimed only at gland obstruction, the treatment may help part of the disease without meaningfully moving the patient’s main complaint. Again, that is not necessarily failure. It may simply mean you treated one layer of the problem but not the dominant one.

That shift in thinking is where improvement begins.

Begin with standardized symptoms

Symptoms matter, but they must be standardized.

If the only symptom assessment you use is, “How are your eyes doing?” you are leaving far too much room for memory, mood, expectation, and uncertainty. Instead, use a standardized symptom questionnaire such as SPEED, OSDI, DEQ, or another tool you trust and use consistently.

This is one of the most important improvements a doctor can make right away.

The patient’s symptoms remain subjective, but the method of measuring them becomes standardized. That allows you to compare the patient to themselves over time. You are no longer relying on vague impressions. You are tracking change.

That matters because a patient may tell you, “I think I’m maybe a little better, but I’m not sure,” while their symptom score shows a meaningful improvement. In that moment, the questionnaire gives both you and the patient something firmer to stand on.

And many times, that is exactly what the patient is looking for. They want you to point to something objective or standardized and say, “Here is how we know you are improving.”

Match the symptoms to the mechanism

Once you have standardized the symptoms, the next step is to match those symptoms to the dominant disease mechanism.

If you believe the problem is primarily inflammatory, then look for findings that support inflammation. That may include corneal or conjunctival staining, MMP-9 positivity, lid margin telangiectasia, conjunctival injection, or other inflammatory signs that align with the patient’s complaints and guide you toward anti-inflammatory treatment.

If you believe the problem is primarily aqueous deficient, then use tests and findings that help you assess tear volume and production. Schirmer scores and tear meniscus height may help you decide whether strategies such as punctal occlusion or therapies that support aqueous function are likely to be useful.

If you believe the problem is primarily evaporative, then assess the meibomian glands in a meaningful way. That includes both how they function and how they look. Expression matters. Structure matters. Meibography matters. Those findings can help determine whether therapies directed at the glands, such as vectored thermal pulsation, TearCare, RF, IPL, or Miebo, make sense for the patient in front of you.

IPL is especially interesting because it may provide a multifactorial benefit. It can help address inflammation and can also improve meibomian gland function. That kind of overlap matters in real-world dry eye care because many patients do not read the textbook before showing up in your chair.

The goal is not to order every test on every patient and create a dry eye scavenger hunt. The goal is to build a reasoning process: standardized symptoms, dominant mechanism, targeted findings, matched treatment.

That is how you move from “I hope this works” to “this is why I chose this.”

Reassess on the timeline of the treatment

Another major improvement in dry eye practice comes from aligning follow-up with the treatment selected.

Not every treatment should be judged on the same timeline.

If you prescribe cyclosporine, you already know that improvement may take four to eight weeks to begin. So a six-week follow-up may be appropriate.

If you perform vectored thermal pulsation, you know from FDA study data that improvement in meibomian gland secretion scores and symptoms may take closer to two months. So follow-up at two months makes sense.

If you place punctal plugs and expect a more immediate effect, a two-week follow-up may be perfectly reasonable.

This seems simple, but it is one of the places doctors often lose confidence. They either check too early, before the treatment had a fair chance to work, or too vaguely, without knowing what exactly they planned to reassess.

You do not judge every glaucoma therapy at the same interval. You should not judge every dry eye therapy at the same interval either.

A good dry eye practice expects the follow-up schedule to be determined, at least in part, by the treatment’s mechanism and expected timeline.

Use the same battery at follow-up

At follow-up, run the same general battery of evaluation you used at baseline.

That does not mean every single visit must be exhaustive. It means the follow-up should be structured in a way that allows comparison. Use the same standardized symptom questionnaire. Reassess the same dominant findings. Compare the patient’s current status to where they started.

This is where the fear of “it didn’t work” begins to dissolve.

Because now the visit is not built around one emotionally loaded question. It is built around comparison.

What happened to the symptom score?
What happened to the staining?
What happened to the tear stability?
What happened to the inflammatory findings?
What happened to gland expression?
What happened to tear volume measures?

Then, and only then, should the patient’s own words be added back into the equation.

Their words matter. They just should not carry the entire weight of the assessment.

What counts as success?

In dry eye, success is often not all-or-none.

That is another expectation doctors need to have.

A treatment may improve inflammation without fully fixing evaporative disease. A gland-directed therapy may improve secretion quality while the patient still needs more help with inflammation or tear volume. A patient may have better staining and a lower SPEED score, yet still not feel “normal.”

That is not failure. That is chronic disease management.

Success may mean:

• a lower symptom score,
• less corneal or conjunctival staining,
• improved tear stability,
• reduced inflammatory findings,
• better meibomian gland function,
• or clearer evidence that your diagnosis and treatment were directionally correct.

That last one matters more than many doctors realize.

Sometimes the first treatment does not solve the entire problem, but it does teach you something useful. It tells you which layer of the disease improved and which layer did not. In that sense, progress can be partial but still clinically meaningful.

Dry eye improvement often happens in layers. If one intervention moves one part of the disease in the right direction, that is progress, not failure. It may simply mean the next step is refinement rather than retreat.

How to begin improving your current dry eye process

If a doctor wants to improve the current state of their dry eye practice, the first step is not buying another device.

The first step is thinking differently.

You need a framework that answers these questions:

Why did I choose this treatment?
What dominant mechanism am I treating?
What baseline symptoms and signs did I document?
When should this treatment reasonably be reassessed?
What findings would tell me it is helping?
What findings would tell me I need to pivot?

Once you can answer those questions consistently, dry eye becomes much less intimidating.

So if you are looking to improve your dry eye care, start here:

Stop treating “dry eye” as a single diagnosis.
Standardize symptoms with a questionnaire.
Identify the dominant mechanism.
Choose treatment that matches that mechanism.
Follow up on the timeline of the treatment selected.
Reassess using the same structured process.
Define success by trends in symptoms and signs, not just by one offhand comment from the patient.

Because the truth is, the sentence “it didn’t work” should almost never be the end of your thinking.

It should be the beginning of your analysis.

What improved?
What did not improve?
What does that tell me about the disease?
What does that tell me about the next step?

That is how you build confidence in dry eye.
That is how you create more predictable care.
And that is how you begin to turn dry eye from a source of apprehension into a real clinical strength.